Felbinac is indicated for the relief of symptoms associated with painful inflammatory conditions of the musculo-skeletal system such as:
- Soft tissue traumas (sprains, strains and contusions).
- Extra-articular rheumatic or inflammatory conditions including bursitis, capsulitis, frozen shoulder, myalgia, tendonitis, tenosynovitis and tennis elbow.
- For the relief of pain and stiffness of rheumatic or non-serious arthritic conditions (i.e. common arthritis).
The primary mechanism of action of Felbinac revolves around its ability to inhibit the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes play a pivotal role in the biosynthesis of prostaglandins, which are lipid compounds that have several crucial functions in the body, including mediating inflammation, pain, and fever. By inhibiting COX enzymes, Felbinac effectively reduces the production of prostaglandins. This reduction attenuates the inflammatory response and provides relief from pain.
Felbinac is highly protein bound, however serum levels following topical application are extremely low, therefore clinical drug interactions are unlikely.
Felbinac is suspected to cause serious birth defects when administered during pregnancy. Traxam 3% w/w Gel is contraindicated in pregnancy. As with other non-steroidal anti-inflammatory agents, which inhibit prostaglandin synthesis, dystocia and delayed parturition were observed when felbinac was administered subcutaneously in animal studies. Traxam 3% w/w Gel should not be used during breast-feeding. Traxam 3% w/w Gel is contraindicated during breastfeeding.
- Undesirable effects may be reduced by using the minimum effective dose for the shortest possible duration. Concomitant long term use of NSAIDs long term, should undergo regular medical supervision to monitor for adverse events. Avoid contact with eyes and mucus membrane.
- The total dose of product should not exceed 25g daily.
- If there is no improvement or the condition is aggravated, the doctor should be consulted. Although the systemic effects should be low, the drug should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulceration, inflammatory bowel disease or bleeding diathesis.
- Elderly patients are particularly susceptible to the adverse effects of NSAIDs. Prolonged use of NSAIDs in the elderly is not recommended. Where prolonged therapy is required, patients should be reviewed regularly.
- As NSAIDs can interfere with platelet function, they should be used with caution in patients with intracranial haemorrhage and
- bleeding diathesis. It should only be used on non-diseased skin.
- To avoid the possibility of photosensitivity, patients should be advised against excessive exposure to sunlight of treated areas.
- This medicine contains 300 mg of alcohol (ethanol) in each 1 g. which is equivalent to 300 mg/g (30%w/w). It may cause burning sensation on damaged skin.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.